Pharmaceutical Holding (Guangdong) Co., Ltd.

Pharmaceutical Holding (Guangdong) Co., Ltd., formerly Tianshili Guangdong Pharmaceutical Co., Ltd., is a drug wholesale enterprise with limited liability. In August 2020, it completed a strategic merger with Chongqing Pharmaceutical (Group) Co., Ltd., and the company was renamed "Pharmaceutical Holding (Guangdong) Co., Ltd.", becoming the provincial platform company of Chongqing Pharmaceutical (Group) Co., Ltd. in Guangdong. In 2019, the company achieved operating revenue of 1.1 billion RMB and total profit of 23 million RMB, representing year-on-year growth of 12% and 19% respectively. It owns 8 subsidiaries at all levels, with 333 employees, distributed across 8 prefecture-level cities in Guangdong Province.
The main business covers hospital pure sales, commercial wholesale, retail chain, terminal distribution, warehousing logistics, and value-added supply chain services for pharmaceuticals, medical devices, traditional Chinese medicines, Chinese herbal decoction pieces, Chinese patent medicines, chemical APIs, chemical drug preparations, antibiotic APIs, antibiotic preparations, biochemical drugs, biological products (including in vitro diagnostic reagents; excluding vaccines), Class II psychotropic substances (preparations), protein anabolic agents, and peptide hormones. The distribution network covers 22 prefecture-level cities in Guangdong.
The company manages 20,000 product specifications, serves 4,400 sales terminals, and has a warehousing area of 20,000 square meters with a total storage capacity of 50,000 items, including over 20,000 piece-picking positions. It is equipped with a "modern warehousing and logistics management system", utilizing electronic labels, tablet picking carts, and conveyor lines with barcode technology-based logistics equipment, ensuring informatized, intelligent, and standardized operations.
Currently, the company is transforming from a traditional distribution enterprise to a modern pharmaceutical business integrating "Internet + medicine" and "wholesale and retail integration". The company will closely rely on the national development strategy of the "Greater Bay Area", establishing a layout with Guangzhou and Shenzhen as dual centers and Zhanjiang as a sub-center. The two wings drive the center, with the nine cities of the Greater Bay Area forming the main center and East and West Guangdong as the two wings, achieving a full network layout. It aims to expand business scale, increase market share, further enhance core competitiveness, and achieve the set goal of growing stronger. The company adheres to the corporate spirit of "dedication to medicine, pursuit of excellence", upholds the core values of "responsibility, people-oriented, harmony, and gratitude", builds a new model for the development of the big health industry in the new era, and creates a new high ground for modern corporate humanistic spirit.